Project Grant R01CA310127
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $658K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $354,658 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025 through July 31, 2030. This award supports fundamental research investigating subclonal P27 (CDKN1B) loss as a driver of aggressive prostate cancer, with particular focus on understanding health disparities affecting Black or African American males who experience prostate cancer mortality...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $477,674 Project Grant to The Johns Hopkins University, effective June 1, 2026 through May 31, 2031, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). This research initiative focuses on molecular imaging of the immune-suppressive tumor microenvironment (TME) in prostate cancer and its response to immune checkpoint inhibitor (CIT) therapy. The project will employ molecular and functional imaging...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $399,129 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with a completion date of June 30, 2027. This award supports research to develop and evaluate improved cancer treatment methods through laboratory and clinical investigation. Specifically, the research leverages a DDX3 inhibitor called RK-33 to alter the metabolic tumor environment in...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $100,228 Project Grant under the Cancer Research Manpower program (CFDA 93.398) effective December 1, 2026, through May 31, 2029. This award supports research training and workforce development in cancer biology aligned with the National Cancer Program's priorities. The funded project investigates the molecular mechanisms of MYC-driven transcriptional reprogramming in prostate cancer...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $155,479 Project Grant effective June 1, 2026 through May 31, 2028 under the Cancer Treatment Research program (CFDA 93.395) to develop and validate an anti-CCRL2 (C-C motif receptor-like 2) antibody-drug conjugate (ADC) targeting high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 mutations. The research addresses a critical clinical need, as patients with...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded The Johns Hopkins University a $1,020,120 Project Grant effective August 1, 2025, through May 31, 2030, to develop and clinically evaluate PROBOT, a novel ultrasound probe and robotic system designed to improve image-guided interventions for prostate cancer diagnosis and treatment. The project delivers a Phase 1 clinical trial evaluating the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Johns Hopkins University a $144,193 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective September 4, 2025 through August 31, 2030. This award provides protected salary support for Dr. Preethi Korangath to serve as a Laboratory Research Specialist in Dr. Robert Ivkov's laboratory, where she will facilitate the completion of Research Project Grants (R01) by leveraging her expertise...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $399,829 Project Grant effective July 1, 2026 through June 30, 2028 under the Cancer Detection and Diagnosis Research program (CFDA 93.394). This research initiative focuses on identifying imaging biomarkers using multiplexed digital pathology data to predict clinical outcomes in breast cancer, with particular emphasis on triple-negative breast cancer (TNBC). The project applies an...
- Federal Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $644,632 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026 through April 30, 2031. This research initiative develops novel antibody-drug conjugates (ADCs) targeting gamma-delta T-cell cancers, which affect approximately 1,000 patients annually in the United States with historically poor survival outcomes (10-15 months median survival). The project addresses...
- Federal Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a Project Grant totaling $591,419 under the Cancer Treatment Research program (CFDA 93.395) for the period May 1, 2026 through April 30, 2031. The grant supports the development of low molecular weight theranostics targeting cluster of differentiation 38 (CD38) protein for multiple myeloma treatment and diagnosis. The primary deliverables include creation of an 18-fluorine-labeled positron emission...